Saturday 17 October 2026
Export NCNA’s income statement to Excel — free account
NuCana PLC Sponsored ADR
NCNA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 16,379.7% and free cash flow grew 55.7%, each against the same quarter a year earlier.
0.99
0.03
−2.94%
Follow NCNA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
5.60 | 1.42 | 1.97 | 2.84 | 6.11 | 12.49 | 10.54 | 15.02 | 32.22 | 13.09 |
Net Debt/EBITDA |
1.23 | 0.30 | 0.55 | 0.97 | 1.28 | 2.72 | 2.08 | 3.55 | 3.64 | 2.23 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.25 | 1.01 | 0.96 | 0.72 | 0.59 | 0.70 | 1.11 | 0.88 | 0.38 | 1.53 |
Capex/Depreciation |
(0.70) | (0.56) | 3.68 | (0.71) | (3.89) | (1.83) | (1.76) | (4.38) | (5.65) | (5.48) |
Interest Coverage |
(1.58) | — | — | (66.05) | (467.48) | (134.09) | (24.50) | (20.71) | (115.65) | (32.20) |
| (195.06%) | (185.84%) | (103.93%) | (57.50%) | (51.24%) | (37.79%) | (28.78%) | (16.11%) | (38.49%) | (10.41%) | |
| (132.97%) | (90.80%) | (64.46%) | (44.36%) | (45.51%) | (34.54%) | (26.53%) | (15.36%) | (36.94%) | (10.00%) | |
ROIC |
(16,444.30%) | 0.00% | 0.00% | 0.00% | (569.78%) | (173.43%) | (138.85%) | (297.89%) | (223.69%) | (107.68%) |
Return on Tangible Assets |
(129.16%) | (500.46%) | (214.80%) | (87.79%) | (66.72%) | (32.35%) | (35.64%) | (17.64%) | (25.25%) | (25.35%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.07 | 0.15 | 0.08 | 0.04 | 0.03 | 0.04 | 0.06 | 0.04 | 0.02 | 0.05 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(4.50) | (2,214.76) | (2,881.23) | (2,815.85) | (3,634.23) | (3,928.20) | (4,929.62) | (2,888.17) | (2,429.65) | (2,772.15) |
Cash per Share |
14.24 | 770.04 | 2,040.59 | 4,984.71 | 7,968.17 | 14,758.57 | 10,207.74 | 16,053.47 | 21,489.00 | 5,644.27 |
Shareholders Equity per Share |
14.28 | 679.34 | 1,763.61 | 4,579.14 | 8,666.84 | 16,764.64 | 12,478.65 | 17,017.45 | 23,153.79 | 7,126.90 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.28 | 679.34 | 1,763.61 | 4,579.14 | 8,666.84 | 16,764.64 | 12,478.65 | 17,017.45 | 23,153.79 | 7,126.90 |
Free Cash Flow |
(10.10) | (24.81) | (30.25) | (29.28) | (37.80) | (29.85) | (32.04) | (18.48) | (12.63) | (13.31) |
Working Capital |
29.10 | 4.60 | 15.35 | 44.05 | 82.36 | 120.26 | 75.30 | 104.15 | 117.36 | 32.32 |
Capital Expenditures |
(0.25) | (0.37) | 2.63 | (0.64) | (5.04) | (2.10) | (1.61) | (2.17) | (1.41) | (0.75) |
Net Current Asset Value |
28.16 | 4.40 | 15.04 | 43.50 | 82.08 | 119.73 | 74.58 | 104.11 | 117.34 | 32.32 |
| Other line items | ||||||||||
Quick Ratio |
5.43 | 1.31 | 1.76 | 2.50 | 5.76 | 11.93 | 9.78 | 14.60 | 31.17 | 11.24 |
Depreciation/Fixed assets |
0.42 | 2.65 | 1.10 | 0.85 | 1.11 | 0.75 | 0.65 | 0.87 | 0.54 | 5.61 |
Cash ROIC |
(15.77%) | (152.81%) | (75.74%) | (29.44%) | (21.85%) | (12.46%) | (21.73%) | (8.73%) | (5.44%) | (21.71%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(4.38) | (2,181.33) | (3,132.14) | (2,754.24) | (3,150.04) | (3,652.47) | (4,681.91) | (2,549.47) | (2,158.25) | (2,615.73) |
Capex per Share |
(0.11) | (33.43) | 250.91 | (61.61) | (484.19) | (275.72) | (247.71) | (338.70) | (271.40) | (156.42) |
Average Receivables |
4.10 | 6.12 | 7.12 | 8.88 | 11.25 | 11.72 | 8.26 | 5.57 | 4.21 | 4.84 |
Average Payables |
2.07 | 3.83 | 5.07 | 4.23 | 2.71 | 2.99 | 3.18 | 2.36 | 1.22 | 1.22 |
Average Assets |
29.11 | 26.74 | 53.32 | 89.29 | 122.47 | 114.07 | 103.05 | 120.28 | 80.53 | 81.99 |
Average Common Equity |
19.84 | 13.06 | 33.07 | 68.88 | 108.77 | 104.26 | 95.01 | 114.66 | 77.30 | 78.78 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates